Dnmt3a-null hematopoietic stem and progenitor cells expand after busulfan treatment
- 20 September 2020
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 91, 39-45.e2
Abstract
No abstract availableKeywords
Funding Information
- March of Dimes Foundation
- National Institutes of Health
- Aplastic Anemia and MDS International Foundation
This publication has 29 references indexed in Scilit:
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014
- Conditioning regimens for hematopoietic cell transplantation: one size does not fit allBlood, 2014
- Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantationBlood, 2013
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustionNature Medicine, 2009
- IFNα activates dormant haematopoietic stem cells in vivoNature, 2009
- Further development of a model of chronic bone marrow aplasia in the busulphan‐treated mouseInternational Journal of Experimental Pathology, 2006
- Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem CellsPLOS Biology, 2004
- Changes in the Proliferative Activity of Human Hematopoietic Stem Cells in NOD/SCID Mice and Enhancement of Their Transplantability after In Vivo Treatment with Cell Cycle InhibitorsJournal of Experimental Medicine, 2002